Research Analysts Set Expectations for IQVIA FY2026 Earnings

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for IQVIA in a note issued to investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings per share of $12.18 for the year, up from their previous forecast of $12.09. The consensus estimate for IQVIA's current full-year earnings is $10.84 per share. Leerink Partnrs also issued estimates for IQVIA's FY2027 earnings at $13.66 EPS and FY2028 earnings at $15.05 EPS.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. IQVIA's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.54 EPS.

Other research analysts have also recently issued reports about the stock. Barclays reduced their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a report on Wednesday, May 7th. Truist Financial lowered their price target on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price target for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Evercore ISI boosted their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $222.45.

IQVIA Stock Down 1.7%

Shares of IQV traded down $2.80 during trading hours on Friday, hitting $162.73. The stock had a trading volume of 1,156,699 shares, compared to its average volume of 1,659,159. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA has a 1-year low of $134.65 and a 1-year high of $252.88. The firm has a 50 day simple moving average of $151.77 and a 200-day simple moving average of $172.43. The firm has a market capitalization of $28.15 billion, a P/E ratio of 22.17, a price-to-earnings-growth ratio of 1.84 and a beta of 1.30.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. American National Bank & Trust purchased a new position in IQVIA during the first quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd raised its stake in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in IQVIA during the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. grew its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.